ATLANTA, Nov. 09, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a pharmaceutical
company that is developing the next generation of antivirals, today announced that Aviragen’s CFO & Executive Vice President Mark
Colonnese will present a corporate overview at the Stifel 2016 Healthcare Conference on Wednesday, November 16, 2016 at 2:15pm ET
in New York.
A live webcast of the presentation can be accessed under "Events and Presentations" in the Investors section of the Company's
website at www.aviragentherapeutics.com or at http://wsw.com/webcast/stifel5/avir.
About Aviragen Therapeutics, Inc.
Aviragen Therapeutics is focused on the discovery and development of the next generation of direct-acting
antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The
Company has three product candidates in active clinical development: vapendavir, an oral treatment for human rhinovirus (HRV) upper
respiratory infections in moderate-to-severe asthmatics currently being evaluated in the Phase 2b SPIRITUS trial; BTA585, an oral
fusion protein inhibitor in Phase 2 development for the treatment and prevention of respiratory syncytial virus (RSV) infections;
and BTA074, a topical antiviral treatment in Phase 2 development for condyloma caused by human papillomavirus types 6 & 11. For
additional information about the Company, please visit www.aviragentherapeutics.com.
Contacts: Mark Colonnese Executive Vice President and Chief Financial Officer Aviragen Therapeutics, Inc. (678) 221-3381 mcolonnese@aviragentherapeutics.com Beth DelGiacco Stern Investor Relations, Inc. (212) 362-1200 beth@sternir.com
